A Long-term Follow-up Study of Patients Who Received MB-105

January 6, 2026 updated by: March Biosciences Inc
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.

Study Type

Observational

Enrollment (Estimated)

40

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Patients who previously received MB-105 and consent to participate

Description

Inclusion Criteria:

Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements

Exclusion Criteria:

N/A

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Open Observation
All patients who previously received MB-105 on another study
Biological: MB-105
This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess long term safety of MB-105 in patients who received MB-105
Time Frame: 15 Years
SAEs
15 Years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess long term efficacy of MB-105 in patients who received MB-105
Time Frame: 15 Years
Time to progression/relapse in those who have not yet relapsed and overall survival
15 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

March Biosciences Inc

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 27, 2026

Primary Completion (Estimated)

October 15, 2040

Study Completion (Estimated)

October 15, 2040

Study Registration Dates

First Submitted

January 6, 2026

First Submitted That Met QC Criteria

January 6, 2026

First Posted (Actual)

January 14, 2026

Study Record Updates

Last Update Posted (Actual)

January 14, 2026

Last Update Submitted That Met QC Criteria

January 6, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • MB-105-202

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Any Patient Treated With MB-105

Clinical Trials on MB-105

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe